Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Total Current Liabilities (2021 - 2025)

Senti Biosciences has reported Total Current Liabilities over the past 5 years, most recently at $14.0 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $14.0 million for Q4 2025, up 6.3% from a year ago — trailing twelve months through Dec 2025 was $14.0 million (up 6.3% YoY), and the annual figure for FY2025 was $14.0 million, up 6.3%.
  • Total Current Liabilities for Q4 2025 was $14.0 million at Senti Biosciences, up from $12.0 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for SNTI hit a ceiling of $18.1 million in Q4 2022 and a floor of $61025.0 in Q2 2021.
  • Median Total Current Liabilities over the past 5 years was $10.7 million (2025), compared with a mean of $10.7 million.
  • Biggest five-year swings in Total Current Liabilities: soared 29065.1% in 2022 and later crashed 41.42% in 2023.
  • Senti Biosciences' Total Current Liabilities stood at $14.5 million in 2021, then rose by 24.14% to $18.1 million in 2022, then dropped by 29.81% to $12.7 million in 2023, then rose by 3.74% to $13.1 million in 2024, then grew by 6.3% to $14.0 million in 2025.
  • The last three reported values for Total Current Liabilities were $14.0 million (Q4 2025), $12.0 million (Q3 2025), and $10.0 million (Q2 2025) per Business Quant data.